Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Baminercept

Drug Profile

Baminercept

Alternative Names: BG 9924; LTβR-Ig; Lymphotoxin-β receptor fusion protein

Latest Information Update: 11 Oct 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec
  • Developer Biogen Idec; National Institute of Allergy and Infectious Diseases
  • Class Antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Lymphotoxin beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Sjogren's syndrome
  • Discontinued Crohn's disease; Rheumatoid arthritis; Ulcerative colitis

Most Recent Events

  • 11 Oct 2018 No recent reports on development identified - Phase-II for Sjogren's syndrome in USA (SC)
  • 01 Nov 2015 The National Institute of Allergy and Infectious Diseases completes phase II trial in Sjögren's syndrome in USA (NCT01552681)
  • 04 Feb 2011 Phase-II clinical trials in Ulcerative colitis (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top